{"@id":"https://bioecon.ru/technology/adenoviral-vector-gene-therapy/","@type":"Technology","cluster":"therapeutics-platforms","formats":{"html":"https://bioecon.ru/technology/adenoviral-vector-gene-therapy/","json":"https://bioecon.ru/api/v1/technology/adenoviral-vector-gene-therapy/index.json"},"id":"adenoviral-vector-gene-therapy","industries":["advanced-therapies"],"lang":"ru","links":{"industries":["https://bioecon.ru/industries/advanced-therapies/"],"suppliers":["https://bioecon.ru/companies/agc-biologics/","https://bioecon.ru/companies/minicircle/","https://bioecon.ru/companies/genscript-probio-genscript/","https://bioecon.ru/companies/novartis/","https://bioecon.ru/companies/lonza-group/","https://bioecon.ru/companies/mosquitomate/","https://bioecon.ru/companies/cryoport-systems/","https://bioecon.ru/companies/astrazeneca/","https://bioecon.ru/companies/kheiron-biotech/","https://bioecon.ru/companies/united-therapeutics/","https://bioecon.ru/companies/tsingke-biotechnology/"]},"maturity":null,"name":"Генная терапия на аденовирусных векторах","regions":["us","cn","eu"],"risk":"low","section":"technology","sector":"health-biomedicine","sources":[{"date":"2026-09-18","entity":"cansino","kind":"vendor","urls":["http://cansinotech.com/detail-3942","https://cansinotech.com/uploadfile/HE/1716444608006.pdf","https://www.cansinotech.com/detail-4484","https://www.hkexnews.hk/listedco/listconews/sehk/2026/0330/2026033003432.pdf"]},{"date":"2026-09-18","entity":"reithera","kind":"vendor","urls":["https://www.nature.com/articles/d43978-021-00089-4","https://www.reithera.com/","https://www.reithera.com/company/about-us/"]},{"date":"2026-09-18","entity":"obio-technology","kind":"vendor","urls":["https://q.stock.sohu.com/cn/688238/index.shtml","https://www.obiosh.com/"]},{"date":"2026-09-18","entity":"genscript-probio","kind":"vendor","urls":["https://www.genscript.com/gsfiles/IPO/Annual_Report_2025.pdf?1327877738=","https://www.prnewswire.com/news-releases/chinas-largest-commercial-gmp-plasmid-manufacturing-facility-is-put-into-operation-genscript-probio-expanding-manufacturing-capacity-again-301439016.html","https://www.prnewswire.com/news-releases/genscript-biotech-corp-reports-strong-fy2025-results-as-integrated-platform-strategy-and-global-execution-drive-high-quality-growth-302714527.html","https://www.probiocdmo.com/gsfiles/techfiles/Making%20Cell%20and%20Gene%20Therapy%20Manufacturing%20Accessible.pdf"]}],"stages":[{"n":1,"title":"Плазмида GMP"},{"n":2,"title":"Банк клеток-продуцентов"},{"n":3,"title":"Производство в биореакторе"},{"n":4,"title":"Очистка"},{"n":5,"title":"Розлив"},{"n":6,"title":"Выпуск и мультирегиональный постав"}],"summary":"Репликационно-дефектные аденовирусные векторы, доставляющие вакцинные антигены и терапевтические гены в промышленном масштабе, — платформенные семейства, проверенные пандемийными испытаниями, суспензионные биореакторы до 2 000 л и цепочка GMP-плазмида-вектор, которая их питает. В таблице четыре поставщика, чьи досье-леджеры несут полные следы источников.","url":"/technology/adenoviral-vector-gene-therapy/","verified":"2026-09-18"}